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Determination of CADESI-03 thresholds for increasing severity
levels of canine atopic dermatitis
Abstract
To evaluate the extent and severity of skin lesions in clinical trials enrolling dogs with atopic dermatitis
(AD), the International Task Force on Canine Atopic Dermatitis recently recommended the use of the
third version of the CADESI. This version of the CADESI was found to exhibit acceptable content,
construct, criterion, inter- and intraobserver reliability and sensitivity to change. The current study was
aimed at determining optimal CADESI-03 cut-off points to separate AD severity categories for future
clinical trials. One hundred and eight dogs with AD were selected based on current diagnosis standards.
At one or more visits, clinicians subjectively rated the severity of AD as 'in remission', 'mild', 'moderate'
or 'severe', and a CADESI-03 score was then determined. In all, 158 CADESI-03 values were recorded
and divided among the four disease severity categories. Receiver-operating characteristics (ROC) curves
were generated at increasing cut-off values to determine the benchmark that would offer optimal
sensitivity and specificity between adjacent categories. Cut-offs of 16, 60 and 120 are proposed at the
interface of remission, mild, moderate and severe categories, respectively. Proposed intervals therefore
are: remission: 0-15; mild AD: 16-59; moderate AD: 60-119; and severe AD: >/= 120. This Task Force
recommends that, whenever applicable and relevant, subgroup analyses of outcome measures, based on
disease severity as determined with these cut-off CADESI-03 values, be preplanned for clinical trials
enrolling dogs with AD. Such subgroup analyses could help determine whether specific interventions
might be more effective in a particular subset of atopic dogs.
© 2008 The Authors. Journal compilation © 2008 ESVD and ACVD.
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Abstract
 
To evaluate the extent and severity of skin lesions in
clinical trials enrolling dogs with atopic dermatitis
(AD), the International Task Force on Canine Atopic
Dermatitis recently recommended the use of the third
version of the CADESI. This version of the CADESI was
found to exhibit acceptable content, construct, crite-
rion, inter- and intraobserver reliability and sensitivity
to change. The current study was aimed at determin-
ing optimal CADESI-03 cut-off points to separate
AD severity categories for future clinical trials. One
hundred and eight dogs with AD were selected based
on current diagnosis standards. At one or more visits,
clinicians subjectively rated the severity of AD as ‘in
remission’, ‘mild’, ‘moderate’ or ‘severe’, and a CADESI-
03 score was then determined. In all, 158 CADESI-03
values were recorded and divided among the four
disease severity categories. Receiver-operating char-
acteristics (ROC) curves were generated at increasing
cut-off values to determine the benchmark that would
offer optimal sensitivity and specificity between adjacent
categories. Cut-offs of 16, 60 and 120 are proposed at
the interface of remission, mild, moderate and severe
categories, respectively. Proposed intervals therefore
are: remission: 0–15; mild AD: 16–59; moderate AD:
60–119; and severe AD: 
 
≥
 
 120. This Task Force recom-
mends that, whenever applicable and relevant, subgroup
analyses of outcome measures, based on disease
severity as determined with these cut-off CADESI-03
values, be preplanned for clinical trials enrolling dogs
with AD. Such subgroup analyses could help determine
whether specific interventions might be more effective
in a particular subset of atopic dogs.
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Introduction
 
In an attempt to better determine the effect of interven-
tions for treatment of atopic dermatitis (AD) in dogs,
clinician investigators have relied on the subjective assess-
ment of various parameters that usually include pruritus
and skin lesions. Over time, various severity scales have
been used to grade the extent and severity of cutaneous
lesions in clinical trials enrolling dogs with AD. Unfortunately,
until recently, none of the proposed morbidity scales had
been evaluated for variability, reliability and sensitivity to
change. From 2004 to 2006, a committee of the International
Task Force on Canine Atopic Dermatitis (ITFCAD) reviewed
all existing scales used in humans and dogs with AD and
a third version of the CADESI (Canine Atopic Dermatitis
Extent and Severity Index) was generated by expanding
previous ones.
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 This revised version – CADESI-03 – was
found to possess adequate content, construct, criterion,
inter- and intraobserver reliability and sensitivity to change
to justify its recommendation for assessment of atopic
skin lesions in clinical trials.
 
3
 
 The CADESI-03 scale presently
consists of the evaluation of the severity (0–5) of four
different lesions at 62 body sites.
As shown in a recent study enrolling dogs with AD,
 
4
 
there are interventions that appear more effective in dogs
with lower CADESI scores compared to those with higher
lesion extent and severity. As a result, when designing
future clinical trials, it might be worthwhile considering the
What is known about the topic of this paper
• The CADESI-03 is a disease severity scale that has been
validated for clinical trials enrolling dogs with atopic
dermatitis.
• At this time, cut-off values of CADESI-03 that separate
disease severity categories are not known.
What this paper adds to the field of veterinary
dermatology
• This study establishes CADESI-03 values that can serve
as benchmarks to separate mild, moderate and severe
atopic dermatitis categories.
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comparison of outcome measures in dogs with variable
disease severity. Moreover, based on the knowledge of
AD pathogenesis and/or mechanism of action of the mole-
cule(s) of interest, investigators might wish to test the
efficacy of a particular intervention in dogs with either
mild, moderate or severe AD. Indeed, drugs with relatively
‘low’ anti-inflammatory or antipruritic potencies may be
better suited for the treatment of mild canine AD, while
those with potent effect would be better designed for
decreasing signs and symptoms in dogs with severe
disease. Furthermore, interventions aimed at preventing
flares of AD might be more suitable for dogs whose disease
is in remission – or of mild severity – while such an
approach would likely fail in dogs with higher disease
activity. Finally, having common benchmarks for frequently
used scales would allow better comparison of data between
clinical trials reporting the effect of similar interventions,
an increasing necessity at the age of systematic reviews,
meta-analyses and evidence-based veterinary dermatology.
The concepts highlighted above illustrate the need to
generate usable benchmarks to separate dogs in remission
from those suffering from mild, moderate or severe AD.
The study described herein aimed at determining CADESI-03
cut-off values that allow the distinction of these three AD
severity categories.
 
Materials and methods
 
Canine subjects and CADESI categorization
 
Clinician members of the ITFCAD selected dogs with AD diagnosed
according to standard methods.
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 All dogs were deemed devoid of
obvious skin infections at the time of examination. Each atopic dog
could be selected one or more times, before and/or after being treated
with anti-inflammatory drugs. At each evaluation visit, clinicians assessed
the severity of AD (remission, mild, moderate or severe) before deter-
mining the CADESI-03 value at that time.
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 The estimation of the
degree of AD severity was made subjectively, taking into account the
extent and intensity of all skin lesions present at the time of examina-
tion. All CADESI-03 scores were then grouped within each of the four
severity categories, each subject contributing one or more value.
 
Determination of disease severity thresholds
 
To determine AD disease severity thresholds (i.e. CADESI-03 cut-off
values), receiver-operating characteristic (ROC) curves were generated
using statistics software (Prism 4.0, GraphPad, San Diego, CA, USA).
CADESI-03 values of each of the three AD categories (mild, moderate
and severe) were compared to the ones in the category immediately
below using increasing CADESI-03 cut-off points. At each of these
threshold values, sensitivities (i.e. the fraction of dogs from the upper
category that had CADESI-03 above the cut-off value) and specificities
(i.e. the proportion of dogs from the lower category that had CADESI-
03 below the cut-off value) were calculated, and ROC curves
(sensitivities vs. [1 minus specificities]) were generated.
 
6
 
 The ‘best’
CADESI-03 cut-off point between the two categories was chosen to
be the closest to the upper left corner ‘ideal’ value, the latter exhibit-
ing 100% sensitivity and specificity (i.e. 1.0 and 0.0 xy coordinates).
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This chosen CADESI-03 cut-off value is associated, therefore, with
the best combination of sensitivity and specificity to separate values
from adjacent severity categories.
 
Results
 
Canine subjects
 
In all, 108 dogs with AD were selected. Ages ranged from
2.5 months to 13.0 years (mean: 5.0; median: 4.5 years)
and the female:male ratio was 0.7. Eight dogs were listed
as crossbred and the other ones were identified as pure-
bred. The following five breeds had more than five dogs
included in this study: German shepherd dog (15 dogs),
Labrador (11), West Highland white terrier (10), golden
retriever (9) and boxer (7); all of these breeds are deemed
predisposed to develop AD.
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CADESI categorization
 
In 77 out of 108 subjects (81%), only one disease severity
and CADESI-03 pair was determined, while in 21 dogs
(19%), multiple assessments were made at two or more
consecutive visits. 
 
In toto
 
, 158 data pairs were obtained,
68 of them (43%) assessed in dogs not receiving any
anti-inflammatory treatment. Details of the spread of
CADESI-03 values for each severity category can be found
in Table 1 and Fig. 1. Even though overlap of data points
occasionally occurred between adjacent categories, their
95% confidence intervals (CI) – or even the 99% CI (data
not shown) – never coincided (Table 1). CADESI-03 values
passed a normality test in each of the four categories, as
shown by the remarkable similarity between means and
medians in each group.
Table 1. CADESI-03 values in atopic dogs with varying disease 
severity
No. Mean Median
95% confidence 
interval
Remission 29 13 9 8–18
Mild AD 43 34 31 27–42
Moderate AD 57 75 77 66–84
Severe AD 29 230 230 195–266
Figure 1. Scatter plot of CADESI-03 values in each disease severity
category, Bar = mean.
 © 2008 The Authors. Journal compilation © 2008 ESVD and ACVD.
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Determination of disease severity thresholds
 
To determine the best possible cut-off point, data from
adjacent categories were compared to each other using
the upper and lower categories as ‘active’ and ‘control’
groups, respectively. ROC curves were generated using
increasing hypothetical CADESI-03 cut-offs (Fig. 2). In
each graph, the upper left-most data set represented
CADESI-03 value that exhibited the best combination of
sensitivity and specificity, and this value therefore was
chosen as ‘best’ cut-off point. For example (upper curve in
Fig. 2), at the cut-off of 16, dogs with mild AD were most
likely to have a CADESI-03 superior to this benchmark
(sensitivity analysis), while those with disease in remis-
sion were most likely to have values inferior to it (specificity
analysis). The same concepts applied to the interfaces of
moderate versus mild (cut-off: 60) and severe versus mod-
erate (cut-off: 120). Of interest is that the greater overlap
of data between mild and remission categories was reflected
with the poorest sensitivity/specificity combination (76
and 80%, respectively) of the three interfaces at the cut-
off point of 16. At the other two interfaces, sensitivity and
specificity combinations were higher (91% and 78% for
moderate vs. mild; 89 and 82% for severe vs. moderate).
Using the cut-offs of 16, 60 and 120 for benchmarks of
mild, moderate and severe AD category, 114 of 158 (72%)
CADESI-03 measurements fell into their adequate severity
group, while 42 (27%) fell in an adjacent one. Only two
measurements (1%) fell in a nonadjacent disease severity
category.
 
Discussion
 
In this study, clinicians with expertise diagnosing AD in
dogs subjectively scored the severity of this disease before
assessing the extent and intensity of skin lesions using
the previously validated CADESI-03 scale as described
before.
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 From 108 dogs with AD, 158 data pairs were
obtained. ROC curves were used to compare CADESI-03
values between adjacent severity categories. Cut-off points
of 16, 60 and 120 were found to possess the highest
sensitivity–specificity combinations between remission,
mild, moderate and severe AD categories, respectively.
When these threshold values were used to separate
disease categories, approximately 70% of the CADESI-03
scores fell into the range associated with the category that
had been subjectively determined for that subject at that
visit. Twenty-seven percent of scores fell in an adjacent
category. These observations highlight the principal limita-
tion of this study; there is no clinical or laboratory parameter
– or combination of parameters – that can be used to
reliably determine the severity of AD in dogs. As a result,
clinicians only had recourse to their observational and
interpretational skills to assess disease severity. It is
foreseeable, and even likely, that a dog with relatively
few skin lesions but marked pruritus might have been
 
Figure 2.
 
Receiver-operating characteristic (BOC) curves. CADESI-03
values from each atopic dermatitis severity category were compared to
data from the category immediately below at increasing CADESI-03
cut-off points. Sensitivities and (1 – specificity) curves were plotted, and
the best possible cut-off point was determined as the upper left-most
point. The no-discrimination line is represented as the dotted bisectrix.
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assessed as suffering from moderate – or even severe
AD. This phenomenon likely explains the 16 observations
of dogs (~10% of data pairs) assessed as suffering from
moderate AD but having CADESI-03 values that fell below
60. Conversely, a dog with widespread or pronounced skin
lesions, albeit with low pruritus, could have been assessed
as having only mild or moderate AD. This situation was
rarely seen, however.
A second limitation of this study is highlighted by the
overlap of CADESI-03 values between the ‘remission’ and
‘mild AD’ categories. This convergence of data may be
due to the relative difficulty of subjectively estimating the
degree of mild erythema or to a possible lack of sensitivity
of the CADESI-03 lesions ‘lichenification’ and ‘self-induced
alopecia’. Indeed, these lesions may not return to normal
values (scores of ‘0’ or ‘1’) for weeks despite a lack of
inflammation or pruritus at the time of examination. As a
result, a dog may have no longer active AD, but its
CADESI-03 score might remain higher than the benchmark
chosen herein.
As a minor observation, it is worth noting that the
CADESI-03 values graded in this study ranged from ‘0’ in
dogs whose atopic signs were deemed in remission to
‘376’, in a dog with severe AD. Even though the maximal
theoretical score of this CADESI-03 is 1240 (five degrees
of severity 
 
×
 
 four lesions 
 
×
 
 62 sites), more than two-thirds
of the possible scores may never be reached, as such
high values would represent a pet with atopic disease of
a severity unacceptable for most pet owners.
It is the hope of this Task Force that the benchmarks
proposed herein will be used in future clinical trials and
mechanistic studies enrolling dogs with AD. These cut-off
points would be helpful for subgroup analyses to test the
efficacy of interventions and/or the association of biomar-
kers in dogs with increasing AD severity. It is likely that some
therapeutic interventions, because of their variable potencies,
might be more effective in dogs with varying morbidity.
Additionally, using similar disease severity, CADESI-03
thresholds will augment the likelihood and usefulness of
pooling data from various clinical trials in meta-analyses.
Such action would increase the level of evidence of efficacy
of interventions to treat canine AD, one of the most
common skin diseases of dogs.
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in two formats, at the bottom of the following site: http://
www.cvm.ncsu.edu/docs/thierry_olivry.html
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Résumé
 
Pour évaluer l’étendue et la sévérité des lésions cutanées dans les essais cliniques portant sur
les chiens souffrant de dermatite atopique (AD), l’International Task Force on Canine AD a récemment
recommandé l’utilisation de la troisième version du CADESI. Cette version du CADESI a été rapportée
comme valable sur son contenu, sa construction, la reproductibilité inter- et intra-examinateur et sa sensi-
bilité. L’étude présentée ici avait pour but de déterminer les valeurs seuils du CADESI-03 pour diviser des
catégories de sévérité d’AD pour les études ultérieures. Cent huit chiens à AD ont été inclus en se basant
sur les critères diagnostiques classiques. A une ou plusieurs visites, des cliniciens ont subjectivement classé
l’AD en ‘rémission’, ‘faible’, ‘modérée’ ou ‘sévère’, et un score CADESI-03 a été réalisé. Au total, 158
valeurs de CADESI-03 ont été établies et divisées dans les 4 catégories de sévérité. Des courbes ont été
réalisées à des valeurs seuils exponentielles pour déterminer la valeur qui permettait la meilleure sensibilité
et spécificité entre les différentes catégories. Des valeurs de 16, 60 et 120 sont proposées à l’interface des
sévérités rémission, faible, modéré et sévère. Les intervalles proposés sont donc: AD en rémission: 0–15;
AD faible: 16–59; AD modérée: 60–119; AD sévère: 
 
≥ 
 
120. Ce groupe de travail recommande que, lorsque
applicable et valable, des analyses d’efficacité se basant sur ces sous-groupes, comme déterminé dans
cette étude à partir du CADESI-03, soient prévues dans les essais cliniques portant sur l’AD. Ces analyses
en sous-groupes pourraient aider à déterminer si un traitement est plus efficace pour un type particulier de
chien atopique. 
 
Resumen
 
Para evaluar la extesión y severidad de las lesiones de piel en las pruebas clínicas con perros
con dermatitis atopica (AD), el grupo internacional de trabajo en Dermatitis Atópica recientemente
recomendo el uso de una tercera versión de CADESI. Esta versión de CADESI tiene contenido, construcción,
criterio, fiabilidad inter e intra-observadores y sensibilidad aceptables. Este estudio tenía el propósito de
 © 2008 The Authors. Journal compilation © 2008 ESVD and ACVD.
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determinar los puntos óptimos de separación de las diferentes categorías de dermatitis atópica en la nueva
versión de CADESI. Ciento ocho perros con dermatitis atópica fueron seleccionados en base a las presentes
indicaciones del diagnóstico. Tras una o más visitas los clínicos veterinarios valoraron subjetivamente la
severidad de la dermatitis atópica como ‘en remisión’, ‘ligera’, ‘moderada’ o ‘intensa’, y se determinó un
valor para el CADESI-03. En total se dieron 158 valores de CADESI-03 divididos en la cuatro categorías de
intensidad de la enfermedad. Con ellos se generaron curvas de características de receptor operador (ROC)
con valores de corte en incremento para determinar el punto que ofrecería una sensibilidad y especifidad
óptimas entre las diferentes categorías. Se proponen valores de corte de 16, 60 y 120 en las transiciones
entre categorías en remisión, ligera, moderada e intensa, respectivamente. Los intervalos propuestos son
pues: remisión 0–15; dermatitis atópica ligera 16–59; moderada 60–119 e intensa 
 
≥ 
 
120. Este grupo de
trabajo recomienda que en pruebas clínicas de dermatitis atópica, y cuando sea aplicable y de importancia,
se preplanifiquen análisis de subgrupos en la valoración de resultados basados en la intensidad de la
enfermedad deteminada por estos puntos de corte. El mencionado análisis de subgrupos podría ayudar a
determinar si particulares intervenciones médicas son más efectivas en una subpoblación particular de
perros con dermatitis atópica.
 
Zusammenfassung
 
Um das Ausmaß und den Schweregrad von Hautveränderungen bei klinischen
Studien, die Hunde mit atopischer Dermatitis (AD) verwenden, zu evaluieren, hat die Internationale Task
Force für Canine AD unlängst die Verwendung einer dritten Version des CADESI empfohlen. Es wurde
befunden, dass diese Version des CADESI einen akzeptablen Inhalt hatte, gut aufgebaut war, einen
Beurteilungsmaßstab, sowie Verlässlichkeit zwischen den Ermittlern und innerhalb eines Ermittlers und
Empfindlichkeit für Veränderung aufwies. Die vorliegende Studie zielte darauf ab, optimale CADESI-03 Cut-
Off Punkte zu bestimmen, um für zukünftige klinische Untersuchungen einzelne AD Kategorien nach Schw-
eregraden zu trennen. Einhundertacht Hunde mit AD wurden nach momentanen diagnostischen Standards
ausgewählt. Bei einer oder mehreren Visiten stuften die Kliniker den Schweregrad der AD subjektiv ein
in ‘in Remission’, ‘mild’, ‘moderat’ oder ‘schwer’, woraufhin ein CADESI-03 Wert bestimmt wurde.
Insgesamt wurden 158 CADESI-03 Werte festgehalten und zwischen den vier Krankheitskategorien mit
unterschiedlichen Schweregraden aufgeteilt. Die ‘Receiver Operator Characteristics’ (ROC) – Kurven
wurden bei zunehmenden Cut-Off Werten erstellt, um den Richtwert, der optimale Sensibilität und Spezifität
zwischen angrenzenden Kategorien bot, zu bestimmen. Cut-off Werte von 16, 60 bzw. 120 wurden an den
Übergängen der Kategorien Remission, mild, moderat bzw. schwer vorgeschlagen. Die beabsichtigten
Intervalle sind daher: Remission: 0–15; milde AD: 16–59; moderate AD: 60–119; und schwere AD: 
 
≥
 
 120.
Diese Task Force empfiehlt, dass, so oft es anwendbar und relevant ist, eine Untergruppenanalyse der
Messergebnisse, basierend auf dem Schweregrad der Krankheit, der durch die Cut-Off CADESI-03 Werte
bestimmt wird, für klinische Versuche bei Hunden mit AD vorausgeplant wird. Derartige Auswertungen der
Untergruppen könnten dabei helfen herauszufinden, ob spezielle Interventionen bei einer bestimmten
Untergruppe von atopischen Hunden effektiver sein könnten.
